Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
11 02 2019
Historique:
received: 11 06 2018
revised: 03 09 2018
accepted: 17 09 2018
pubmed: 10 11 2018
medline: 26 3 2020
entrez: 10 11 2018
Statut: ppublish

Résumé

The aims of the present study were to investigate the applicability of quantitative flow ratio (QFR) in patients with 3-vessel disease and to demonstrate the impact of functional SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score derived from QFR (fSS The applicability of QFR in patients with 3-vessel disease and the feasibility of fSS All lesions interrogated using instantaneous wave-free ratio and/or fractional flow reserve in the SYNTAX II trial were retrospectively screened and analyzed for QFR. The diagnostic performance of QFR was investigated using hybrid wire-derived pressure assessment (instantaneous wave-free ratio and fractional flow reserve), used in the trial as a reference. Patients with analyzable QFR in 3 vessels were stratified according to fSS QFRs were analyzable in 71.0% of lesions (836 lesions). The diagnostic performance of QFR to predict binary wire-based ischemia was substantial (area under the curve 0.81, accuracy 73.8%), with a positive predictive value of 85.9%. Independent predictors of diagnostic discordance were lesions in side branches, involvement of bifurcation or trifurcation, and small vessel. According to the 2-year patient-oriented composite endpoint, fSS QFR demonstrated substantial applicability in patients with 3-vessel disease. The fSS

Sections du résumé

OBJECTIVES
The aims of the present study were to investigate the applicability of quantitative flow ratio (QFR) in patients with 3-vessel disease and to demonstrate the impact of functional SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score derived from QFR (fSS
BACKGROUND
The applicability of QFR in patients with 3-vessel disease and the feasibility of fSS
METHODS
All lesions interrogated using instantaneous wave-free ratio and/or fractional flow reserve in the SYNTAX II trial were retrospectively screened and analyzed for QFR. The diagnostic performance of QFR was investigated using hybrid wire-derived pressure assessment (instantaneous wave-free ratio and fractional flow reserve), used in the trial as a reference. Patients with analyzable QFR in 3 vessels were stratified according to fSS
RESULTS
QFRs were analyzable in 71.0% of lesions (836 lesions). The diagnostic performance of QFR to predict binary wire-based ischemia was substantial (area under the curve 0.81, accuracy 73.8%), with a positive predictive value of 85.9%. Independent predictors of diagnostic discordance were lesions in side branches, involvement of bifurcation or trifurcation, and small vessel. According to the 2-year patient-oriented composite endpoint, fSS
CONCLUSIONS
QFR demonstrated substantial applicability in patients with 3-vessel disease. The fSS

Identifiants

pubmed: 30409759
pii: S1936-8798(18)31945-9
doi: 10.1016/j.jcin.2018.09.023
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-270

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Taku Asano (T)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan.

Yuki Katagiri (Y)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Chun Chin Chang (CC)

ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands.

Norihiro Kogame (N)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Ply Chichareon (P)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Kuniaki Takahashi (K)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Rodrigo Modolo (R)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Erhan Tenekecioglu (E)

ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands.

Carlos Collet (C)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, Universitair Ziekenhuis Brussels, Brussels, Belgium.

Hans Jonker (H)

Cardialysis, Rotterdam, the Netherlands.

Clare Appleby (C)

Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Azfar Zaman (A)

Department of Cardiology, Freeman Hospital Newcastle, Newcastle upon Tyne, United Kingdom.

Nicolas van Mieghem (N)

ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands.

Neal Uren (N)

Department of Cardiology, The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Javier Zueco (J)

Department of Cardiology, Hospital Universitario Valdecilla, Cantabria, Spain.

Jan J Piek (JJ)

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Johan H C Reiber (JHC)

Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.

Vasim Farooq (V)

Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University Hospitals, Manchester, United Kingdom.

Javier Escaned (J)

Hospital Clinico San Carlos IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Adrian P Banning (AP)

Department of Cardiology, John Radcliffe Hospital, Cardiology, Oxford, United Kingdom.

Patrick W Serruys (PW)

ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: patrick.w.j.c.serruys@gmail.com.

Yoshinobu Onuma (Y)

ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH